Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Geron Corp (GERN)

Geron Corp (GERN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,027,752
  • Shares Outstanding, K 638,355
  • Annual Sales, $ 76,990 K
  • Annual Income, $ -174,570 K
  • EBIT $ -63 M
  • EBITDA $ -75 M
  • 60-Month Beta 0.62
  • Price/Sales 5.83
  • Price/Cash Flow N/A
  • Price/Book 4.16

Options Overview Details

View History
  • Implied Volatility 112.38% (-7.98%)
  • Historical Volatility 58.87%
  • IV Percentile 41%
  • IV Rank 12.93%
  • IV High 429.98% on 10/10/25
  • IV Low 65.22% on 06/04/25
  • Expected Move (DTE 8) 0.1785 (10.95%)
  • Put/Call Vol Ratio 0.12
  • Today's Volume 964
  • Volume Avg (30-Day) 1,348
  • Put/Call OI Ratio 0.43
  • Today's Open Interest 68,753
  • Open Int (30-Day) 74,427
  • Expected Range 1.4515 to 1.8085

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.03
  • Number of Estimates 5
  • High Estimate -0.02
  • Low Estimate -0.04
  • Prior Year -0.04
  • Growth Rate Est. (year over year) +25.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.2600 +29.37%
on 01/20/26
1.6899 -3.54%
on 02/11/26
+0.2000 (+13.99%)
since 01/12/26
3-Month
1.0500 +55.24%
on 11/19/25
1.6899 -3.54%
on 02/11/26
+0.3900 (+31.45%)
since 11/12/25
52-Week
1.0400 +56.73%
on 11/07/25
2.8350 -42.50%
on 02/14/25
-1.1600 (-41.58%)
since 02/12/25

Most Recent Stories

More News
Geron Plans to Announce Fourth Quarter and Full Year 2025 Financial Results on February 25, 2026

FOSTER CITY, Calif., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today...

GERN : 1.6300 (+1.24%)
Geron Corporation Provides 2026 Financial Guidance

2026 RYTELO ® (imetelstat) net product revenue expected in the range of $220 to $240 million 2026 total operating expenses expected in the range of $230 to $240 million Expected top-line...

GERN : 1.6300 (+1.24%)
Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

FOSTER CITY, Calif., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial stage biopharmaceutical company, today reported that, effective December 17, 2025, it granted stock...

GERN : 1.6300 (+1.24%)
Geron Corporation Announces Strategic Restructuring Plan to Position the Company for Long-Term Value Creation

Restructuring Supports RYTELO ® U.S. Commercial Strategy and Investment in Clinical Development Expected to Reduce 2026 Projected Operating Expenses FOSTER CITY, Calif., Dec. 11, 2025 (GLOBE...

GERN : 1.6300 (+1.24%)
Geron Corporation Presents New Data at ASH 2025 Highlighting the Relationship Between Treatment-Emergent Cytopenias and Clinical Benefit of RYTELO® (Imetelstat) in Lower-Risk MDS

Oral presentation from pooled analyses of the IMerge population suggests that treatment-emergent cytopenias may reflect on-target effects associated with meaningful clinical outcomes, including hemoglobin...

GERN : 1.6300 (+1.24%)
Geron: Q3 Earnings Snapshot

Geron: Q3 Earnings Snapshot

GERN : 1.6300 (+1.24%)
Geron Corporation Reports Third Quarter 2025 Financial Results and Recent Business Highlights

Achieved $47.2 million in RYTELO® net product revenue in Q3 2025 Completed enrollment in Phase 3 IMpactMF clinical trial evaluating imetelstat in relapsed/refractory...

GERN : 1.6300 (+1.24%)
Geron Corporation to Present at Upcoming Investor Conferences

Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced that Harout Semerjian, Chief Executive Officer,...

GERN : 1.6300 (+1.24%)
Geron Corporation Announces Five Presentations Selected for ASH 2025 Highlighting Clinical Activity of RYTELO® (imetelstat) in Myeloid Hematologic Malignancies

New analysis from the Phase 3 IMerge clinical trial, accepted as an oral presentation, explores relationship between treatment-emergent cytopenias and clinical response in LR-MDS ...

GERN : 1.6300 (+1.24%)
Geron Plans to Announce Third Quarter 2025 Financial Results on November 5, 2025

Geron Corporation (Nasdaq: GERN), a commercial stage biopharmaceutical company aiming to change lives by changing the course of cancer, today announced that it will release its third quarter financial...

GERN : 1.6300 (+1.24%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Strongest short term outlook on maintaining the current direction.

See More Share

Business Summary

Geron is a late-stage clinical biopharmaceutical company focused on the development and potential commercialization of a first-in-class telomerase inhibitor, imetelstat, in hematologic malignancies. The Company currently is conducting two Phase 3 clinical trials: IMerge in lower risk myelodysplastic...

See More

Key Turning Points

3rd Resistance Point 1.7658
2nd Resistance Point 1.7067
1st Resistance Point 1.6683
Last Price 1.6300
1st Support Level 1.5708
2nd Support Level 1.5117
3rd Support Level 1.4733

See More

52-Week High 2.8350
Fibonacci 61.8% 2.1493
Fibonacci 50% 1.9375
Fibonacci 38.2% 1.7257
Last Price 1.6300
52-Week Low 1.0400

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar